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Aims: This paper investigates the presence of M3 muscarinic acetylcholine re-
ceptor autoantibody present in the serum of patients with primary Sjögren 
syndrome (pSS). Main methods: We detected the levels of M3mAChR peptide 
IgG, PGE2, IL-1β in serum of SS patients using the enzyme-linked immune 
sorbent assay (ELISA). To measure the quantity of nitrite/nitrate, we used 
Griess reagent system. Key findings: Titres of M3mAChR antibody in sera 
from SS patients are significantly enhanced compared to healthy subjects 
(control). The enhancement of these autoantibodies is accompanied by the 
increase of the levels of PGE2, IL-1β and nitrite/nitrate in serum. Under in vi-
tro conditions, the synthetic human M3 peptide impaires the increment of 
M3mAChR antibody but not that of nati-Ro/SSA antibody. In positive an-
ti-Ro/SSA antibody patients, the increment of M3mAChR peptide IgG and the 
measured pro-inflammatory substances is related. Significance: On this basis, 
anti M3mAChR peptide IgG can be said to act as a modulator of the immune 
system and to play a role in the host-chronic increment of proinflammatory 
substances in SS patients with positive Ro/SSA antibody. This association be-
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1. Introduction 
Sjögren’s syndrome (SS) is a systemic autoimmune disease primarily affecting 
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the exocrine glands. Although clinically characterized by dry eyes (keratocon-
junctivitissicca) and dry mouth (xerostomia), a series of extra-glandular manife-
stations can also develop [1]. The disease occurs either in a primary form (pSS) 
or in association with other autoimmune diseases (associated form, aSS) such as 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic 
sclerosis (SSc). SS affects mostly women, represented by the ratio of 9 female to 1 
male and a prevalence in the range of 0.1% to 4.8%, depending on the popula-
tion examined and the classification criteria used [2] [3] [4] [5]. 
The presence of serum autoantibodies in the course of SS is of key signific-
ance. They are therefore usually used as biomarkers for the classification and 
diagnosis of pSS and aSS [4] [5]. However, other autoantibodies not currently 
used in clinical practice such as anti-M3 muscarinic acetylcholine receptor (an-
ti-M3mAChR), have also been described in pSS/aSS [6] [7] [8] as useful markers 
[9] [10]. 
It is known that anti-Ro/SSA and anti-La/SSB antibodies are directed against 
ribonucleoprotein complexes [11]. Their localization is mainly cytoplasmic [12] 
and the increased expression of Ro52 in SS and SLE patients is probably impli-
cated positively or negatively in the alteration of cellular immune responses and 
in the increased apoptosis observed in pSS patients [13] [14]. Ro52 in pSS can 
act as a negative regulator of interferon production, ubiquitination and degrada-
tion of the transcription factors IRF-3 [15], IRF-7 [16] and IRF-8 inducing major 
alterations in cytokine expression and production [17]. There is a higher preva-
lence of extra-glandular clinical manifestations in pSS/aSS anti-Ro/anti-La anti-
body positive patients [5] [18]. In patient with pSS, the presence of these antibo-
dies increases the risk of neonatal congenital heart block [19] or neonatal SLE [20]. 
One of the remaining unsolved questions in pSS is the relationship between 
anti-Ro/SSA and anti-M3mAChR antibodies and their role in the production of 
pro-inflammatory cytokines (IL-1β/PGE2-nitric oxide) in the pathogenesis of 
pSS. Against this background, the aim of the present work is to analyze the dis-
tribution of positive or negative serum anti-Ro and anti-M3mAChR antibodies 
in a population of pSS patients. In addition, we investigate the relation between 
the production of IL-1β, PGE2 and nitric oxide (detected by nitrate/nitrite pro-
duction) and if the presence of these autoantibodies is in view of finding out 
whether they are able to alter or participate in the pathogenesis of SS disease. 
2. Material and Methods 
2.1. Patients 
The subjects of this study were 26 pSS patients (14 anti-Ro/SSA positive, 12 an-
ti-Ro/SSA negative) and 24 healthy volunteers all female, (age 39 - 54 years) se-
lected from the metropolitan area of Buenos Aires (Table 1). The diagnosis of 
pSS fulfilled the criteria described by Vitali et al. [21] and was given by means of 
a positive biopsy with a score focus of 3.8 ± 0.07. Anti-Ro/SSA positivity or an-
ti-Ro/SSA negativity was determined by enzyme-linked immunosorbent assay 
(ELISA). 
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Table 1. Characteristics of the study populations. 
Demographics Factors 
pSS Patients 
(n = 26) 
Healthy Subjects 
(n = 24) 
Anti-Ro (+) Anti-Ro (−) Anti-Ro (+) Anti-Ro (−) 







Age, mean ± SD years 39.2 ± 12.9 48.6 ± 14.5 40 ± 11.8 42.6 ± 13.8 
Xerostomia ++++ + ---- ---- 
Xerophthalmia ++++ + ---- ---- 
ANA positive 
Anti-Ro/SSA positive antibodies, % 
Anti-M3mAChR positive antibody, % 

















Values are expressed as mean ± SEM. Values in parenthesis are the percentages. Anti-M3mAChR peptide 
IgG: *P < 0.001 between anti-M3mAChR peptide IgG anti-Ro (+) and anti-Ro (−) patients and healthy sub-
jects. ND: not detected. ANA: antinuclear antibody. Clinical state of patients with pSS: + leve, ++++ severe. 
 
The protocol was approved by the Ethics Committee of the University of Bu-
enos Aires (Buenos Aires, Argentina) and complied with the tenets of the Dec-
laration of Helsinki. All subjects signed a written informed consent. 
2.2. Serological Studies 
Anti-Ro-SSA procedure: Saline-soluble extractable nuclear antigens (ENA) were 
obtained from human spleen in phosphate buffered saline (PBS) for anti-Ro. Pa-
tient sera were tested undiluted and diffusion was carried out at room tempera-
ture in a humidified chamber for 48 hours. Precipitin lines were identified by 
comparison with reference sera. ELISAs for total anti-Ro (60kD and 52kD Ro- 
proteins) was performed with a commercial Kit based on purified antigens (Or-
gentecDiagnostika, Mainz, Germany) and the assays were carried out according 
to the manufacturer’s protocols on an automated ELISA instrument (Radim, 
Pomezia RM, Italy). Values greater than 25 UI/ml were considered positive. 
Purification of human IgG: The serum IgG fraction from patients with pSS 
and from normal individuals (control) was isolated using protein G affinity 
chromatography as described elsewhere [9]. Briefly, sera were loaded onto the 
protein G affinity column (Sigma-Aldrich, St Louis, MO, USA) equilibrated with 
1 M Tris-HCl (pH 8.0) and the columns were washed with 10 volumes of the 
same buffer. The IgG fraction was eluted with 100 mM glycine-HCl, pH 3.0, and 
immediately neutralized. The concentration and purification of IgG were deter-
mined using a radial immunodiffusion assay. 
Anti-M3 peptide IgG procedure: The IgG fraction from 26 patients with pSS 
and 24 healthy subjects was independenthly subjected to affinity chromatogra-
phy on the synthesized peptide covalently linked to AfiGel 15 gel (Bio-Rad, 
Richmond, CA,USA) as described by Reina et al. [9]. Briefly, the IgG fraction 
was loaded onto the affinity column equilibrated with PBS. The non-peptide 
fraction was first eluted with the same buffer. Specific anti-peptide antibodies 
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were then eluted with 3 M KSCN and 1 M NaCl, followed by immediate exten-
sive dialysis against PBS. The IgG concentration of non-anti-peptide antibodies 
and specific anti-muscarinic receptor peptide antibodies was determined by a 
radial immunodiffusion assay. Their immunological reactivity against musca-
rinic M3 receptor peptide was evaluated by ELISA. The concentration of the af-
finity-purified anti-M3 peptide IgG (1 × 10−7 M) increased optical density (mean 
± SEM, 2.4 ± 0.2). The non-anti-M3 peptide IgG fraction from the column 
showed OD values (0.27 ± 0.06) similar to those of normal IgG from healthy in-
dividuals taken as control (0.26 ± 0.05). The normal IgG fraction purified by af-
finity column chromatography gave a negative result (0.30 ± 0.03). ELISA was 
performed as described previously [6]. 
2.3. IL-1β and PGE2 Procedures 
Serum IL-1β and PGE2 were measured by ELISA, carried out according to the 
manufacturer’s protocols (IL-1β Enzyme Immune Assay Kit, Cayman Chemical 
Company, Ann Arbor, MI, USA; PGE2Biotrack Enzyme Immune Assay System, 
Amersham Bioscience, Piscateway, NJ, USA). Normal values of IL-1β range 
from 0.2 to 5.8 pg/ml, with an average of 3.2 ± 1.4 pg/ml in healthy individuals. 
The optical density (OD) cutoff value of PGE2 was 4.4 ± 0.33 ng/ml and that of 
IL-1β 2.0 ± 0.02 pg/ml. All serum samples were frozen promptly after collection 
and kept at −80˚C until used for PGE2 and IL-1β and determinations. The PGE2 
and IL-1β results are expressed as ng/ml and pg/ml, respectively. 
2.4. Nitrate and Nitrites Assay 
The 20 μl serum samples were mixed with an equal volume of 100 μl of Griess 
reagent (Ingredient A: 0.1% naphthalene diamine dihydrochloride at a final 
concentration of 5 mmol/l; Ingredient B: 1% sulfanilamide at a final concentra-
tion of 5 mmol/l in orthophosphoric acid) in a 96 well microtiter plate (NUNC, 
Roskilde, Denmark). Nitric oxide concentrations were determined by a nitrate/ 
nitrite colorimetric assay kit (Cayman Chemical Co, Ann Arbor, MI, USA) and 
measured spectrophotometrically at 540 nm using a microplate reader (Reader 
Model 230 S; OrganonTeknika, Boxtel, The Netherlands) following the criteria 
of Green et al. [22]. The nitrate and nitrites values are expressed as μM/ml. 
2.5. Statistical Analysis 
The statistical significance of the difference between the groups was determined 
by Student’s 2-tailed t-test for unpaired data. ANOVA test and Student-New- 
man-Keuls test were also performed when pair-wise multiple comparisons were 
necessary. In all cases, P values less than 0.05 were considered significant. 
3. Results 
Table 1 summarizes the clinical and laboratory characteristics of all patients 
studied with pSS Ro (+), Ro (−) and healthy subjects (control) based on demo-
graphics data and the values of detected serum antibodies. 
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To demonstrate the presence of serum IgG directed against M3mAChR anti-
bodies, we performed an ELISA assay. The coating antigen used for this purpose 
was a M3 human synthetic peptide corresponding to the amino acid sequence of 
the second extracellular loop (K-R-T-V-P-D-N-Q-C-F-I-Q-F-L-S-N-P-A-V-T- 
F-G-T-A-I) of human glandular M3mAChR. 
The scatter gram of Figure 1 shows the optical density values (OD) of each 
the 14 Ro-positive [Ro (+)] pSS patients and 12 Ro-negative [Ro (−)] pSS pa-
tients. The OD values obtained with the reactive autoantibodies were always 
more than two (2) standard deviation (SD) higher than those of healthy subjects, 
who were negative as Ro (−) patients in this study system. 
It also shows that a significantly higher levels of anti-M3mAChR peptide IgG 
(P < 0.001)was present in Ro(+) patients sera as compared to that of Ro(−) pSS 
patients. This difference was not statistically significant in the case of healthy 
subjects as compared to pSS Ro(−) patients whereas it was significant between 
healthy subjects and pSS Ro(+) ones (P < 0.001). 
Figure 2 shows that serum IL-1β levels are significantly elevated in patients 
with pSSRo(+) as compared to those of healthy subjects and pSS Ro(−) patients 
(P < 0.001). Neither the cytokine levels in patients with SS Ro(−) nor in healthy 
subjects were statistically significant. 
 
 
Figure 1. Scatterogram showing the immunoreactivity of 
circulating IgG against M3 synthetic peptide IgG in 14 
patients with anti-Ro(+), 12 patients with anti-Ro(−) and 
24 healthy subjects used as control; individual OD values 
(1/30 dilution); OD cutoff value of 0.30 ± 0.03 anti- 
M3mAChR peptide IgG; P < 0.001 between anti-Ro(+) 
versus healthy subject and anti-Ro(−); non-significant 
differences between anti-Ro(−) and healthy subjects. 




Figure 2. Scatterogram showing the levels of IL-1β in 
serum of patients with pSS; values for each serum sample 
(1/30 dilution) from 14 pSS Ro(+), 12 pSS Ro(−) and 24 
healthy subjects; IL-1β cutoff value 2.60 ± 0.14; P < 0.001 
between anti-Ro(+) patients versus Ro(−) and healthy 
subjects; no significant differences between patients with 
SS Ro(−) and healthy subjects. 
 
Figure 3 shows the values of PGE2 in Ro(+) versus Ro(−) pSS patients. It can 
be seen that the serum levels of PGE2 did not differ significantly between the two 
study groups and are significantly elevated compared to healthy subjects (P < 
0.001). 
The NO levels in patients with pSS were significantly higher than those in 
healthy subjects (Figure 4). Mean nitrate/nitrite concentrations in patients with 
pSS were 27.8 ± 2.3 (P < 0.001) µM while those in healthy subjects and Ro(−) pa-
tients were significantly lower, rating 12.1 ± 4.6 and 10.8 ± 3.1 µM (P < 0.0001) 
respectively. 
It should be noticed that Ro(+) pSS patients were found to have high levels of 
anti-M3 mAChR peptide IgG accompanied with an increased serum level of 
IL-1β, PGE2 and NO, although the level of PGE2 and NO observed in Ro(+) or 
Ro(−) pSS patients remain the same. 
4. Discussion 
In this study we demonstrate that the presence of anti-Ro(+) antibodies in the 
sera of pSS patients is associated with an increased serum concentration of an-
ti-M3mAChR antibodies. 
Functional studies reveal in addition that the presence of anti-Ro(+) antibo-
dies and anti-M3mAChR antibodies is accompanied by increased levels of serum 
IL-1β, PGE2 and NO. The immune cytokine IL-1β could be, in part, responsible 
for the increment of the levels of the pro-inflammatory mediators such as, PGE2  




Figure 3. Scatterogram showing the levels of PGE2 in an-
ti-Ro(+) and anti-Ro(−) pSS patients; individual values 
for each serum sample (1/30 dilution) from 14 pSS 
Ro(+), 12 pSS Ro(−) and 24 healthy subjects; PGE2 cutoff 
value 0.40 ± 0.01; P < 0.001 between anti-Ro(+) and an-
ti-Ro(−) versus healthy subjects; no significant difference 
between SS Ro(+) and SS Ro(−) patients. 
 
 
Figure 4. Histogram showing a comparison between NO 
expressed as nitrates/nitrites (µM/ml) concentration in 
serum of pSS patients Ro(+), pSS patients Ro(−) and 
healthy subjects used as controls. Mean ± SEM of 14, 12 
and 24 studied individuals respectively in each case; *P < 
0.001 versus healthy subjects. 
S. Reina et al. 
 
249 
and NO. These in turn, contribute to the severity of the inflammatory reaction 
occurring at the glandular and/or extraglandular sites. 
It is important to note that one of the characteristic features of pSS is the 
presence of autoantibodies against Ro/SSA antigen. The role of this antibody in 
the pathogenesis of SS is generally considered as a nonspecific molecule that be-
comes a target in pSS, possibly as a modulator of the altered innate immunity 
[23]. However anti-M3mAChR autoantibodies, which are organ-specific, could 
also be a specific factor participating in the pathogenesis of SS [13]. 
Based on the above, it could be speculated that viral infection of salivary gland 
epithelial cells leads to over expression of Ro 52 (a metabolic product of the an-
ti-Ro antibody) as a defensive mechanism both to suppress viral replication and 
to protect the host from activation of the INF system. It could also be said that 
INF drives glandular inflammation accompanied by cellular lysis and apoptosis 
[13] [24]. Furthermore the Ro can be said to cause oxidative damage to glandu-
lar epithelial cells due to its capacity to stimulate proinflammatory cytokines 
such as IL-1β and PGE2, leading to the maintenance of glandular tissue inflam-
mation. All of these changes are also observed in the course of SLE [25]. 
Since increased levels of anti-M3mAChR antibodies are found to have preva-
lence in Ro(+) pSS patients and this antibody is organ specific, it may be rea-
sonably considered that its increment may be implicated in etiopathology of the 
disease. This is the case since anti-M3mAChR IgG binds to, and activates, the 
mAChR subtype M3 of the salivary gland. This produces xerostomia and glan-
dular parasympathetic dysfunction, which in the chronic course of the disease, 
results also in severe extraglandular manifestations [9] [10] [11]. 
At this point of the discussion, anti Ro(+) and anti M3mAChR antibodies 
could be considered useful both in the diagnosis and prognosis of pSS. They 
could also help to identify more active patients in whom the clinical behaviour is 
not clear and in this way serve as a new biomarker. 
Our results are supported by recent studies describing an association between 
prolongated QTc interval [26], and the increment of anti-Ro antibodies in con-
nective tissue disease (CTD) [27] [28]. Studies using human cardiac tissues 
showed that IL-1β affects the myocardium and treatment with IL-1β for a few 
hours decrease heart contractility [29]. It is important to remark that the relev-
ance between circulating IgG against M3 synthetic peptide IgG and levels of 
IL-1β, could indicate some participation in the prolonged QTc intervals that oc-
curs in connective tissue diseases [27] [28]. 
The fact is that the breakdown of self-tolerance in the activation of CD4+ T 
helper cells and B cells disturbances occurring in the course of pSS is not enough 
to maintain the disease. Some organ-specific new protein (could be a glandular 
M3mAChR autoantibody) is required as a new component to spread the antigen 
and cause the parasympathetic dysfunction with all the sicca symptoms. 
5. Conclusion 
In summary, we have found enhanced titres of anti-Ro(+) and anti M3mAChR 
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peptide IgG in patients with pSS as well as a high level of IL-1β, PGE2 and NO. 
This may be related to the time of the evolution of the disease or the active or 
non-active form of the disease. As IL-1β affects the equilibrium of the immune 
system, we consider that this cytokine initiates the process which culminates 
with the increment of the levels of proinflammatory substances such as PGE2 
and NO together with those of anti-M3mAChR peptide IgG. All of these events 
contribute to the pathogenesis of this syndrome. 
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